Mutifactorial Analysis of Risk Factors for Reduced Bone Mineral Density in Patients with Crohn's Disease

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2006 Sep 29

PMID 17007022

Citations 18

Authors

Sarah A Bartram

Robert T Peaston

David J Rawlings

David Walshaw

Roger M Francis

Nick P Thompson

Affiliations

Soon will be listed here.

Abstract

Aim: To determine the prevalence of osteoporosis in a cohort of patients with Crohn's disease (CD) and to identify the relative significance of risk factors for osteoporosis.

Methods: Two hundred and fifty-eight unselected patients (92 M, 166 F) with CD were studied. Bone mineral density (BMD) was measured at the lumbar spine and hip by dual X-ray absorptiometry. Bone formation was assessed by measuring bone specific alkaline phosphatase (BSAP) and bone resorption by measuring urinary excretion of deoxypyridinoline (DPD) and N-telopeptide (NTX).

Results: Between 11.6%-13.6% patients were osteoporotic (T score < -2.5) at the lumbar spine and/or hip. NTX levels were significantly higher in the patients with osteoporosis (P < 0.05) but BSAP and DPD levels were not significantly different. Independent risk factors for osteoporosis at either the lumbar spine or hip were a low body mass index (P < 0.001), increasing corticosteroid use (P < 0.005), and male sex (P < 0.01). These factors combined accounted for 23% and 37% of the reduction in BMD at the lumbar spine and hip respectively.

Conclusion: Our results confirm that osteoporosis is common in patients with CD and suggest that increased bone resorption is the mechanism responsible for the bone loss. However, less than half of the reduction in BMD can be attributed to risk factors such as corticosteroid use and low BMI and therefore remains unexplained.

Citing Articles

Osteoporosis Complications in Crohn's Disease Patients: Factors, Pathogenesis, and Treatment Outlines.

Baban Y, Edicheria C, Joseph J, Kaur P, Mostafa J Cureus. 2022; 13(12):e20564.

PMID: 35103143 PMC: 8772394. DOI: 10.7759/cureus.20564.

Impact of Cigarette Smoking on the Risk of Osteoporosis in Inflammatory Bowel Diseases.

Ratajczak A, Szymczak-Tomczak A, Rychter A, Zawada A, Dobrowolska A, Krela-Kazmierczak I J Clin Med. 2021; 10(7).

PMID: 33916465 PMC: 8038608. DOI: 10.3390/jcm10071515.

Diversity of Gut Microbiota Affecting Serum Level of Undercarboxylated Osteocalcin in Patients with Crohn's Disease.

Wagatsuma K, Yamada S, Ao M, Matsuura M, Tsuji H, Iida T Nutrients. 2019; 11(7).

PMID: 31288415 PMC: 6683014. DOI: 10.3390/nu11071541.

Intestinal inflammation without weight loss decreases bone density and growth.

Irwin R, Raehtz S, Parameswaran N, McCabe L Am J Physiol Regul Integr Comp Physiol. 2016; 311(6):R1149-R1157.

PMID: 27733383 PMC: 5256970. DOI: 10.1152/ajpregu.00051.2016.

The role of physical exercise in inflammatory bowel disease.

Bilski J, Brzozowski B, Mazur-Bialy A, Sliwowski Z, Brzozowski T Biomed Res Int. 2014; 2014:429031.

PMID: 24877092 PMC: 4022156. DOI: 10.1155/2014/429031.

References

Dresner-Pollak R, Karmeli F, Eliakim R, Ackerman Z, Rachmilewitz D . Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease. Am J Gastroenterol. 2000; 95(3):699-704. DOI: 10.1111/j.1572-0241.2000.01850.x. View

Schulte C, Dignass A, Mann K, Goebell H . Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. Scand J Gastroenterol. 1999; 34(7):696-702. DOI: 10.1080/003655299750025903. View

Compston J, Judd D, Crawley E, Evans W, Evans C, Church H . Osteoporosis in patients with inflammatory bowel disease. Gut. 1987; 28(4):410-5. PMC: 1432817. DOI: 10.1136/gut.28.4.410. View

Uebelhart D, Schlemmer A, Johansen J, Gineyts E, Christiansen C, Delmas P . Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab. 1991; 72(2):367-73. DOI: 10.1210/jcem-72-2-367. View

Hansen M, Overgaard K, Riis B, Christiansen C . Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ. 1991; 303(6808):961-4. PMC: 1671323. DOI: 10.1136/bmj.303.6808.961. View

Kyle J . Crohn's disease in the northeastern and northern Isles of Scotland: an epidemiological review. Gastroenterology. 1992; 103(2):392-9. DOI: 10.1016/0016-5085(92)90826-k. View

Pigot F, Roux C, Chaussade S, Hardelin D, Pelleter O, du Puy Montbrun T . Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci. 1992; 37(9):1396-403. DOI: 10.1007/BF01296010. View

Felson D, Zhang Y, Hannan M, Anderson J . Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J Bone Miner Res. 1993; 8(5):567-73. DOI: 10.1002/jbmr.5650080507. View

Edelstein S, Barrett-Connor E . Relation between body size and bone mineral density in elderly men and women. Am J Epidemiol. 1993; 138(3):160-9. DOI: 10.1093/oxfordjournals.aje.a116842. View

10.

Croucher P, Vedi S, Motley R, Garrahan N, Stanton M, Compston J . Reduced bone formation in patients with osteoporosis associated with inflammatory bowel disease. Osteoporos Int. 1993; 3(5):236-41. DOI: 10.1007/BF01623826. View

11.

Scharla S, Minne H, Lempert U, Leidig G, Hauber M, Raedsch R . Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis). Exp Clin Endocrinol. 1994; 102(1):44-9. DOI: 10.1055/s-0029-1211264. View

12.

Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L . Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut. 2000; 46(2):176-81. PMC: 1727806. DOI: 10.1136/gut.46.2.176. View

13.

Scott E, Gaywood I, Scott B . Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology. Gut. 2000; 46 Suppl 1:i1-8. PMC: 1766735. DOI: 10.1136/gut.46.suppl_1.i1. View

14.

Ghosh S, Cowen S, Hannan W, Ferguson A . Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology. 1994; 107(4):1031-9. DOI: 10.1016/0016-5085(94)90227-5. View

15.

Garnero P, Shih W, Gineyts E, Karpf D, Delmas P . Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994; 79(6):1693-700. DOI: 10.1210/jcem.79.6.7989477. View

16.

Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M . Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology. 1995; 108(2):417-22. DOI: 10.1016/0016-5085(95)90068-3. View

17.

Kanis J . Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. 1994; 4(6):368-81. DOI: 10.1007/BF01622200. View

18.

Silvennoinen J, Karttunen T, Niemela S, Manelius J, Lehtola J . A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut. 1995; 37(1):71-6. PMC: 1382771. DOI: 10.1136/gut.37.1.71. View

19.

Silvennoinen J, Risteli L, Karttunen T, Risteli J . Increased degradation of type I collagen in patients with inflammatory bowel disease. Gut. 1996; 38(2):223-8. PMC: 1383027. DOI: 10.1136/gut.38.2.223. View

20.

Silvennoinen J, Lehtola J, Niemela S . Smoking is a risk factor for osteoporosis in women with inflammatory bowel disease. Scand J Gastroenterol. 1996; 31(4):367-71. DOI: 10.3109/00365529609006412. View